While the COVID-19 pandemic is still raging in various parts of China, a new virus called Langya henipavirus was discovered recently and there have been at least 26 cases of the disease. Its close relative is the Nipah virus, which has a mortality rate as high as 75%, so the appearance of the Langya virus has attracted great attention from the outside world. However, Chinese officials have little to say on the subject. Any relevant announcements, official media doesn’t seem to report.

Shaoxing said, on August 4, 2022, Professor Liu Wei and Professor Fang Liqun at the Institute of Microbial Epidemiology, the Academy of Military Medical Sciences, The Academy of Military Science of China, with Professor Wang Linfa at Duke Medical School – NUS Singapore, and others collaborated and published an article in the New England Journal of Medicine (NEJM), indicating that an animal-origin Henipavirus that can infect humans was found in Shandong and Henan provinces, and named Langya virus, LayV.

The Henipavirus is currently known to be capable of infecting humans and causing death, and is classified as a biosafety level 4 virus. However, other related henipaviruses have also been found in bats, rodents, and shrews (mole-like rodent). During the recent surveillance of febrile patients with animal contact in eastern China, a genetically distinct Henipavirus was identified in one patient’s throat swab, which is Langya virus.

In this study, the authors said, the LayV is similar to that of other henipaviruses.

The researchers’ investigation later showed that 26 cases of Langya virus infection were found in Shandong and Henan provinces. The symptoms of these 26 people were fever, fatigue, a cough, loss of appetite, muscle aches, nausea, headaches, vomiting, a decrease in blood platelets, a decrease in white blood cells, impaired liver function, impaired renal function.

Du Chengzhe, a doctor from Taiwan, pointed out in a Facebook post that this virus is different from current common viruses, that the shrew can be a natural host for this virus, its seropositivity rate (host) is as high as 27%, far exceeding the 5% in dogs and 2% in goats, and is a potential threat.

According to ipkmedia.com, regarding the Langya virus, Zhuang Renxiang, a spokesman for Taiwan’s Central Epidemic Command Center, said that there is no history of close contact or contact history among patients infected with this virus. It is estimated that current human infection may be incidental, nor is there evidence of human-to-human transmission among close contacts of the 9 trace cases, but it is not possible at present. Any conclusions can be drawn and close follow-up is required.

However, according to Vision Times, until now, China’s official media has not reported an epidemic of Langya virus. On Aug. 7, when a reporter searched for “Langya virus” on Baidu, only the Chinese version of the article from the the New England Journal of Medicine came up. Another mainland netizen retweeted a screenshot of a Taiwanese media report and wondered, “Is there the Langya Virus? is this real or fake? I don’t see anyone discussing it.”

Currently, the outside world does not know if CCP officials concealed the truth about this new virus, but because they had previously concealed the pandemic in Wuhan, has the world concerned about the new virus.

Langya virus is a relative of Nipah virus of the same genus Henipavirus, according to previous medical records, the mortality rate caused by Nipah virus is as high as 75%.

RTI on Feb. 1, 2021 said that the Access to Medicine Foundation, a nonprofit organization based in the Netherlands, had warned about the Nipah virus, which has a high mortality rate, from 40% to 75% mortality, broke out in China. Jayasree KIyer, executive director of Access, also reminded that should the Nipah virus break out in China, it would be a pandemic of drug-resistant viral infections. Mainland China’s state media, however, did not provide an official explanation or reminder to the masses.

Sign up to receive our latest news!

By submitting this form, I agree to the terms.